Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
1.560
-0.080 (-4.88%)
May 5, 2025, 4:00 PM EDT - Market closed
Q32 Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
19.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | -6.65M | -13.30M | -200.00% |
Dec 31, 2022 | 6.65M | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionQTTB News
- 6 days ago - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - PRNewsWire
- 20 days ago - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PRNewsWire
- 2 months ago - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting - PRNewsWire
- 2 months ago - Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting - PRNewsWire
- 2 months ago - Q32 Bio to Participate in Upcoming March Investor Conferences - PRNewsWire
- 3 months ago - Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata - PRNewsWire
- 3 months ago - Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - PRNewsWire